TerminatedNot Applicable

Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT

Stopped: interim analysis found no difference in LB rate and lower than expected event rate

Canada88 participantsStarted 2000-03

Plain-language summary

To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies randomized to either low molecular weight heparin plus aspirin versus aspirin alone.

Who can participate

Age range18 Years – 44 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * history of two or more unexplained consecutive pregnancy losses prior to 32 weeks * presence of one of the panel of autoantibodies/thrombophilia markers * confirmed pregnancy Exclusion Criteria: * SLE * known peptic ulcer disease * sensitivity to ASA or heparin * previous thrombotic event * geographic distance from clinic * failure to consent

What they're measuring

To investigate whether treatment with LMW heparin plus ASA results in an increased rate of livebirths compared to treatment with ASA alone.

Timeframe: Duration of pregnancy

Trial details

NCT IDNCT00564174

SponsorMount Sinai Hospital, Canada

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Recurrent Pregnancy Loss trials